EDITAS MEDICINE, INC. Net Income (Loss) Available to Common Stockholders, Diluted
EDITAS MEDICINE, INC. (EDIT) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$220.43 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2023-02-22
- EDITAS MEDICINE, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$220.43M.
- EDITAS MEDICINE, INC. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$192.50M.
- EDITAS MEDICINE, INC. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$115.98M.
- EDITAS MEDICINE, INC. net income (loss) available to common stockholders, diluted for fiscal 2019 was -$133.75M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|
| 2022-12-31 | -$220.43M 10-K · filed 2023-02-22 | |
| 2021-12-31 | -$192.50M 10-K · filed 2023-02-22 | -$191.50M 10-K · filed 2022-02-24 |
| 2020-12-31 | -$115.98M 10-K · filed 2023-02-22 | |
| 2019-12-31 | -$133.75M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |